FDA grants priority review to Insmed ARIKAYCE MAC lung disease sNDA, PDUFA set for Jan. 28, 2027

Bitget2026/09/21 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted Insmed’s sNDA for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review.
PDUFA target action date set for Jan. 28, 2027.
Filing seeks full approval, supported by Phase 3b ENCORE results showing improved respiratory symptoms, higher culture conversion versus multidrug therapy alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210700PR_NEWS_USPR_____NY52070) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA grants priority review to Insmed ARIKAYCE MAC lung disease sNDA, PDUFA set for Jan. 28, 2027

You may also like

Crypto prices